Moderna claims that its booster significantly raises antibodies against Omigran

The company announced Monday that the booster shot of the modern corona virus vaccine significantly raises the level of antibodies that can inhibit the Omigron variant.

The news comes as Omigron is advancing rapidly around the world, and most corona virus vaccines are visible The infection could not be prevented From the most contagious variant.

Moderna’s results show that the currently approved 50 microgram booster dose — half the dose given for primary immunization — has increased approximately 37 times the level of antibodies. The full dose of 100 micrograms was even more powerful, boosting antibody levels 83-fold compared to pre-boost levels, Modernna said.

Both doses produced side effects comparable to those seen after the two-dose primary series. But the 100 microgram dose showed slightly more frequent adverse reactions compared to the approved 50-microgram dose.

The results based on laboratory tests did not capture the full extent of the body’s immune response to the virus. Although vaccines do not prevent infection from variant, it is expected to prevent severe disease in most people.

The data were not published or reviewed by independent experts. Moderna says it is preparing a manuscript with data to be published online.

Pharmaceutical companies Pfizer and Bioendech Announced earlier this month The booster shot of their vaccine also increased the level of antibodies against Omigran.

Moderna tested a third shot of several versions of its vaccine, each for 20 people. Prior to the increase, all individuals had low levels of antibodies that could prevent Omigran infection. On the 29th day, after receiving the third shot, both the 50-microgram and 100-microgram doses of the current vaccine sharply increased the antibody level.

READ  Отчет и основные моменты квалификации Гран-при Великобритании 2022: Сайнс Пип Ферстаппен забьет первый гол в квалификации Гран-при Великобритании с дождем

The company also tested «multivalent» booster displays that contain mutations found in beta and delta variants, many of which are in Omicron. 300 to 600 people were recorded in each of those successive trials. The 50-microgram and 100-microgram levels of multivalent boosters increased antibody levels to similarly high levels, Modernna said.

Considering how quickly Omigran is marching around the world, Moderna said the company will focus its near-term efforts on additional shots of the original vaccine. It plans to test a booster shot specific to the Omicron variant early next year and add the Omicron to the multivalent booster.

«In response to this highly pervasive variation, Moderna will rapidly advance the Omicron-specific booster candidate in clinical trials if needed in the future,» said Stéphane Bancel, CEO of Moderna.

Добавить комментарий

Ваш адрес email не будет опубликован.